Development of a Multimodal Index to Improve the Predictive Value of Success in Weaning From Mechanical Ventilation
1 other identifier
observational
126
1 country
1
Brief Summary
Weaning from mechanical ventilation (MV) is a complex process in which patients are liberated from the ventilator. Prolongued weaning and weaning failure, defined as the need for reintubation, have different adverse effects, including prolongation of MV, intensive care unit (ICU) and hospital stay, and are also associated with increased incidence of ventilator-associated pneumonia and high mortality. The rate of weaning failure is high, even when the classic extubation criteria are met, so it is necessary to improve scores that allow predicting and determining the ideal time for MV withdrawal. The aim of this study is to design a new multimodal index to predict and optimize weaning results in a personalized way, based on the use and interpretation of data derived from continuous monitoring of critically ill patients. The new multimodal index, in addition to classical respiratory parameters, will include parameters related to patient-ventilator interaction (asynchronies), diaphragmatic function, cardiovascular status and autonomic nervous system function (ANS). The investigators have designed a prospective observational study that will include 126 critical patients from a medical-surgical ICU that meet the classical criteria for weaning. The management of the patients, as well as the weaning process, will be carried out following the usual protocol. In addition to the classical weaning predictor data, data on the patient-ventilator interaction and the function of the autonomic nervous system will be collected by means of specific software (BetterCare). Cardiovascular and diaphragmatic function will be evaluated using ultrasound. Based on the advanced analysis of data from different devices collected throughout the mechanical ventilation period, it will be designed a "personalized" weaning score that should improve the accuracy of the decision-making process and therefore reduce morbidity and mortality. Additional benefits would include lowering health care costs without increasing adverse events.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 31, 2020
CompletedFirst Posted
Study publicly available on registry
September 18, 2020
CompletedStudy Start
First participant enrolled
April 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedFebruary 7, 2024
February 1, 2024
2 years
August 31, 2020
February 6, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Multimodal index for weaning prediction evaluation
Number of successful weanings evaluated through the new multi-modal index compared to the classic indexes
48 hours after mechanical ventilation withdrawal
Secondary Outcomes (1)
Predictive value of patient-ventilator interaction
From day 1 of mechanical ventilation until 48 hours after mechanical ventilation withdrawal
Interventions
Respiratory parameters, analytic values, lung ultrasound and echocardiography
Eligibility Criteria
Patients admitted to the ICU of the Parc Taulí Universitary Hospital undergoing MV and starting the weaning process according to the protocol established for usual clinical care practice.
You may qualify if:
- Patients with MV\> 24 hours.
- Patients with orotracheal tube.
- Patients who meet the classic criteria of weaning from the MV defined as:
- Improvement or resolution of the cause required for MV. PaO2\> 60mmHg with FiO2≤0.4 and PEEP ≤8cm H2O. Glasgow Coma Score\> 10 Temperature \<38 ° C. Hemoglobin\> 8g / dL No need for vasoactive drugs or at doses \<5μg / kg / min Obtaining informed consent.
You may not qualify if:
- Tracheostomy patients.
- Patients with neurological pathology with involvement of the brainstem.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Candelaria De Haro
Sabadell, Barcelona, 08208, Spain
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical doctor and Doctor of Philosophy
Study Record Dates
First Submitted
August 31, 2020
First Posted
September 18, 2020
Study Start
April 4, 2022
Primary Completion
April 1, 2024
Study Completion
December 1, 2024
Last Updated
February 7, 2024
Record last verified: 2024-02